2021
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
de Haan F, Bolarinwa O, Guissou R, Tou F, Tindana P, Boon W, Moors E, Cheah P, Dhorda M, Dondorp A, Ouedraogo J, Mokuolu O, Amaratunga C. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies? PLOS ONE 2021, 16: e0256567. PMID: 34464398, PMCID: PMC8407563, DOI: 10.1371/journal.pone.0256567.Peer-Reviewed Original ResearchConceptsAfrican countriesTriple artemisinin-based combination therapiesKey actor groupsMarket prospectsBurkina FasoActor groupsInnovation systemRegulatory arrangementsDepth interviewsInternational fundersArtemisinin-based combination therapyProfit motivesQualitative studySoutheast AsiaGroup discussionsCountry levelAfrican countiesCurrent artemisinin-based combination therapiesLarger communityCountriesDrug marketAcceptability issuesBroad implicationsWorld Health OrganizationMarket readiness
2018
In Vivo Antiplasmodial Activity of Two Sahelian Plant Extracts on Plasmodium berghei ANKA Infected NMRI Mice
Bonkian L, Yerbanga R, Koama B, Soma A, Cisse M, Valea I, Tinto H, Ouedraogo J, Guigemde T, Traore/Coulibaly M. In Vivo Antiplasmodial Activity of Two Sahelian Plant Extracts on Plasmodium berghei ANKA Infected NMRI Mice. Evidence-based Complementary And Alternative Medicine 2018, 2018: 6859632. PMID: 29977316, PMCID: PMC5994278, DOI: 10.1155/2018/6859632.Peer-Reviewed Original ResearchArtemisinin-based combination therapyWorld Health OrganizationNMRI miceBody weightUncomplicated malaria treatmentAntiplasmodial activityVivo antiplasmodial activityPercentage of reductionFour-day treatmentControl of malariaExtract/Thin blood smearsCombination therapyMalaria treatmentPrimary treatmentControl groupDay fiveBlood smearsCandidate drugsHerbal medicineHealth OrganizationMalariaLeaf decoctionTreatmentParasitaemia
2017
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis
Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, Ouedraogo JB, Borrmann S, Mwai L, Nsanzabana C, Price RN, Dahal P, Sambol NC, Parikh S, Nosten F, Ashley EA, Phyo AP, Lwin KM, McGready R, Day NP, Guerin PJ, White NJ, Barnes KI, Tarning J. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLOS Medicine 2017, 14: e1002212. PMID: 28072872, PMCID: PMC5224788, DOI: 10.1371/journal.pmed.1002212.Peer-Reviewed Original ResearchConceptsPiperaquine exposureDose regimenFalciparum malariaSmall childrenLarger childrenDay 7 plasma concentrationsThree-compartment disposition modelUncomplicated Plasmodium falciparum malariaNonlinear mixed-effects modellingPopulation pharmacokinetic propertiesIndividual Participant Data Meta-AnalysisPlasmodium falciparum malariaPopulation pharmacokinetic modelData Meta-AnalysisGuideline development groupUseful therapeutic lifeYoung childrenWorldWide Antimalarial Resistance NetworkConcentration-time dataWorld Health OrganizationDose occasionPiperaquine pharmacokineticsMixed-effects modellingUncomplicated malariaDose regimens